blood

The Boon of Blood

A Look Inside NIH’s Department of Transfusion Medicine

a patient receiving blood during a surgery

The essential role of blood in our bodies has been recognized as far back as the time of ancient Greece, when the Greek physician Hippocrates included it in his list of four ‘humors’ that influence our health and emotions. Since then, scientists have vastly expanded our understanding of the dark red liquid running through our veins and arteries. Nowadays, researchers and technicians like those in NIH’s Department of Transfusion Medicine (DTM) can not only safely remove blood from one person and transfuse it into another, but they can also transform it into incredible forms of therapy.

The Life-Saving NIH Blood Bank

Blood Donors Play Critical Role in IRP’s Mission

Hal Wilkins (left) and Dr. Kamille West-Mitchell (right) pose with a sign for the NIH Blood Bank

The NIH IRP is full of vampires. Hundreds of patients at the NIH Clinical Center — not to mention scientists in roughly 200 IRP labs — depend on blood provided by NIH’s very own blood bank.

Conveniently located in the NIH Clinical Center, the NIH Blood Bank collects roughly 4,000 units of ‘whole blood’ each year — the process most people think of when they think of donating blood. It also receives more than 2,000 annual donations of specific blood components, which are collected via a process that separates them from other parts of the blood and returns the rest to the donor’s body. Most of those donations gather blood-clotting platelets, but the NIH Blood Bank also occasionally collects oxygen-carrying red blood cells and infection-fighting ‘convalescent plasma.’

Treatment Corrects Consequences of Accelerated Cellular Aging

Mouse Study Demonstrates Promise of New Therapy for Rare Genetic Conditions

time warp

If you ask a scientist how old you are, you may be surprised to get a different answer depending on who you’re talking to. That’s because age can be measured both ‘chronologically’ — in terms of time — and at a cellular level. Indeed, certain genetic mutations cause cells to age faster, leading to a host of health problems. Fortunately, a recent IRP study performed in mice suggests that boosting levels of a specific molecule could help alleviate some of those patients’ symptoms.

Starving Malaria in Red Blood Cells

Understanding How Parasite Feeds May Lead to New Treatments

red blood cells

World Malaria Day, commemorated annually on April 25, highlights the need to end an infectious disease that sickens nearly 250 million people around the world each year, killing more than 600,000 in regions where it is common. Children are particularly susceptible to its deadly effects.

Unfortunately, there is still no highly effective vaccine against malaria, so management is mostly limited to preventive measures like bed nets and medications that treat the infection, which must be taken over an extended period to effectively treat the disease and stop it from spreading. However, the speed with which the malaria parasite, Plasmodium falciparum, adapts to antimalarial drugs has created a critical need for novel treatments — a need that IRP researchers led by Joshua Zimmerberg, M.D., Ph.D., are taking a unique approach to filling.

Bringing Out the Big Guns Against Blood Cancer

IRP Research Shows Benefits of More Intensive Treatments for Certain Patients

woman receiving chemotherapy treatment

Fate can be cruel, especially when it comes to a rare, highly fatal blood cancer called acute myeloid leukemia (AML). Even when months of intensive chemotherapy appear to cause a complete remission of the disease — meaning doctors cannot detect any remaining cancer cells in a patient’s body — roughly half of those patients see the cancer return within two years, or even as soon as six months. Sadly, most of them don’t survive their second bout with the disease.

As a medical student, IRP senior investigator Christopher Hourigan, M.D., D.Phil., thought this outcome was unfair. More than that, he thought it indicated that the standard ways doctors determined if an AML patient was in remission were inadequate, and that remission might not even be the right goal. That’s why he has focused his career on finding ways to detect, prevent, and treat AML recurrence, known in his field as ‘relapse’.

“I was a scientist before I became a doctor, and it was really eye-opening to me, when I started to practice medicine, how difficult some of the treatment decisions were and how limited the information available was to inform those decisions,” Dr. Hourigan says.

Pain Research Center Accelerates IRP Pain Studies

Dedicated Staff and Cutting-Edge Technology Helps Solve Pain’s Many Mysteries

collage of researchers working with volunteers

For such a common ailment, pain remains a significant mystery. Part of the challenge of studying it is that it occurs in so many conditions and can vary from a mild ache to life-altering misery. Fortunately for both pain patients and IRP researchers studying pain, the NIH Pain Research Center has the technology and expertise to power new discoveries about pain in its many, complex forms.

On March 31 and April 1, NIH’s National Center for Complementary and Integrative Health (NCCIH) hosted a two-day virtual symposium titled “Tackling Pain at the National Institutes of Health: Updates From the Bench, the Clinic, and the New NIH Pain Research Center,” which featured presentations from a number of IRP scientists exploring important questions related to pain. Read on to learn more about some of the research discussed during that event, including efforts examining pain in patients with rare diseases, early-phase clinical trials of a new pain treatment, and investigations of how psychological factors can affect the way people experience pain.

Introducing NIH’s Newest Lasker Scholars

Program Gives Boost to Early Stage Investigators

Alison Boyce, Ian Myles, Jacqueline Mays, Yogen Kanthi, and Stephanie Chung

If TV shows like The Voice and America’s Got Talent are any indication, there are many extremely talented people out there who could become huge successes if presented with the right opportunity. This is no less the case in science, with thousands of extremely bright individuals quietly toiling away in their mentors’ labs as they await the chance to establish research programs of their own.

Fortunately, initiatives like the NIH’s Lasker Clinical Research Scholars Program exist to boost promising young researchers on to the next stage of their careers. Every year, the Lasker program allows a small group of early stage physician-scientists to establish their own labs at the NIH and carry out independent clinical research there for at least five years.

The five talented investigators selected as 2020 Lasker Scholars are pursuing a wide range of research questions, from how the immune system influences blood clotting to the mechanisms driving a rare and devastating skeletal disorder. Read on to learn more about the latest crop of researchers ramping up IRP labs of their very own.

Blood Test Predicts Premature Labor

First-Trimester Blood Analysis Could Enable Earlier, More Effective Intervention

mother and baby sleeping next to each other

Imagine a world in which pregnant women routinely travel to places of healing and meet with wise sages who examine a bit of their blood to divine when their babies will be born. While this may sound like something out of Greek mythology, it may soon become a reality, as IRP researchers have developed a test that was able to use blood samples taken early in pregnancy to identify women who would later deliver their babies prematurely.

Cellular Garbage Aids Quest for Alzheimer’s Blood Test

Experimental Approach Predicts Future Alzheimer’s Diagnoses

exosomes

If you looked through my garbage, you would probably find a litany of apple cores (my favorite fruit) and a couple fundraising requests from my alma mater. Similarly, scientists can learn a lot about what is going on in cells by examining their trash. IRP researchers recently developed a blood test that may be able to predict Alzheimer’s disease years before the onset of symptoms by examining packages of waste products from neurons.

A Look Back at the Legacy of Theodor Kolobow

The IRP has been home to a number of truly remarkable scientists who spent decades making discoveries and developing technologies that would go on to improve the lives of many. One of these giants was Theodor Kolobow, M.D., who passed away in March of last year at age 87. During his many years at the NIH's National Heart, Lung, and Blood Institute (NHLBI), Dr. Kolobow made momentous contributions to the study of our lungs and cardiovascular systems, including advancements in the development of artificial organs and key insights into the biological processes behind acute lung injury. 

Dr. Kolobow's legacy lives on not only through his colleagues' fond memories and his lasting influence on medical practice, but also through the NIH's historical archives. Read on for a tour through Dr. Kolobow's life and career, as can only be told by the Office of NIH History. 

Dr. Theodor Kolobow